SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD DEC 04
MCX SILVER DEC 04
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD DEC 04
MCX SILVER DEC 04
MCX CRUDEOIL NOV 19
MCX NATURALGAS OCT 27
USD/INR
EUR/INR
GBP/INR
JPY/INR

Market snaps 4-day gaining streak; Sensex falls 148 points

S&P 500, Nasdaq edge higher as investors cling to stimulus hopes

See world oil demand peaking in 2030, says IHS Markit's Daniel Yergin

Rupee settles 4 paise higher at 73.54 against US dollar

Business

Zydus Cadila gets USFDA nod for multiple sclerosis treatment drug

Updated : September 25, 2020 01:21 PM IST

Drug firm Zydus Cadila on Friday said it has received final approval from the US health regulator to market Dimethyl Fumarate delayed-release capsules, indicated for the treatment of patients with relapsing forms of multiple sclerosis. Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera)in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing.

Zydus Cadila said in its approval, the USFDA noted that Zydus was one of the first abbreviated new drug application applicants to submit a substantially complete ANDA and is, therefore, eligible for 180 days of generic drug exclusivity along with other first ANDA applicants.

”The USFDA granted approval following entry of judgment in favour of Zydus Cadila and other ANDA applicants by the United States District Court for the District of Delaware, holding that the only unexpired patent covering Tecfidera is invalid,” the company added.

Zydus Cadila said the newly approved medication will be manufactured at the group’s formulation manufacturing facility at the SEZ, Matoda. The group now has 303 approvals and has so far filed over 390 abbreviated new drug applications since the commencement of the filing process in 2003-04.

Also Read: Zydus Cadila gets tentative approval for generic diabetes drug

Cipla on Friday said it has also received final approval from the USFDA for dimethyl Fumarate capsules. Quoting IQVIA (IMS Health) data, Cipla said Tecfidera had US sales of approximately USD 3.8 billion for the 12-month period ending July 2020.

Shares of Cadila Healthcare were trading 0.39per cent lower at Rs 377.50 apiece on BSE.

You May Also Like

Hong Kong fines Goldman Sachs Asia $350 million over 1MDB

Hong Kong fines Goldman Sachs Asia $350 million over 1MDB

Asian Paints Q2 beats estimates; net profit rises 1% to Rs 851 crore and margin improves

Asian Paints Q2 beats estimates; net profit rises 1% to Rs 851 crore and margin improves

Bajaj Auto Q2 net profit falls 19% YoY to Rs 1,138.2 crore; Revenue down 7%

Bajaj Auto Q2 net profit falls 19% YoY to Rs 1,138.2 crore; Revenue down 7%

Trending on CNBC-TV18

Live TV

recommended for you